30 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA
PRAX-628 Phase 1 study showed consistent safety profile and target engagement
10-K
EX-10.3
r3zfnk4wob52ay
17 Mar 21
Annual report
8:33am
10-K
tyypkjgh dgq7orvwk
17 Mar 21
Annual report
8:33am
10-Q
gqk0mvb6721xgu81bo
23 Nov 20
Quarterly report
4:16pm
424B4
abqje22lsinzx0
16 Oct 20
Prospectus supplement with pricing info
4:02pm
S-1/A
EX-10.1
zsv 8ez8l84e6
9 Oct 20
IPO registration (amended)
6:09am
S-1/A
5iuwzq52a he
9 Oct 20
IPO registration (amended)
6:09am